Studies find high response rates against HCV genotypes without interferon
Studies find high response rates against HCV genotypes without interferon
By Gene Emery
NEW YORK (Reuters Health) - Doctors reported high success
rates Sunday in treating different genotypes of the hepatitis C
virus using varying combinations of drugs that don't carry the
side effects of interferon.
The new results were released during the Digestive Disease
Week 2014 meeting in Chicago and online by the New England
Journal of Medicine.
About 184 million people have HCV worldwide. It causes more
than 350,000 liver disease deaths annually. In some countries,
the infection rate can be as high as 5%.
Current therapy carries a high risk of significant side
effects, such as flu-like symptoms, neuropsychiatric problems
and cytopenias.
Two studies known as PEARL-III and PEARL-IV looked at
previously-untreated people with genotypes 1a and 1b, which are
responsible for the vast majority of HCV infections. Genotype 1a
is most common in North America and is believed to be harder to
cure because it is more likely to develop resistance. Genome 1b
is particularly common in Europe and East Asia.
Both studies looked at drug combinations with and without
ribavirin, which is administered based on body weight. All of
the volunteers were otherwise treated with daily doses of 150 mg
of the protease inhibitor ABT-450, 100 mg of ritonavir and 25 mg
of ombitasvir, all combined into one pill, plus 250 mg of
dasabuvir twice a day. The patients were evaluated after 12
weeks of treatment.
In the 305 people with genotype 1a, 97.0% responded with the
addition of ribavirin (95% confidence interval 93.7 to 100)
compared to 90.2% of those who did not receive it (95%
confidence interval 86.2 to 94.3). The rate of virologic failure
was just 2.0% with ribavirin and 7.8% without.
Among the 419 patients carrying genotype 1b, the presence of
ribavirin made little difference. The sustained virologic
response rate was 99.5% with the extra drug (95% confidence
interval 98.6 to 100) and 99.0% without (95% confidence interval
97.7 to 100). Only one patient had virologic failure, and that
patient was receiving the ribavirin regimen.
Twelve patients suffered serious adverse events. In the
genotype 1a study, three patients were receiving ribavirin and
one was not. In the genotype 1b study, the eight patients were
evenly split between the two groups.
The most common side effects were headache, seen in 23% to
28% of patients, and fatigue, reported by 21% to 46%, with the
incidence higher in the genotype 1a group. Nausea, insomnia and
pruritus tended to be higher among patients receiving ribavirin
as part of their therapy.
Ribavirin also significantly suppressed hemoglobin levels in
roughly half the patients.
As a result, some people with blood problems, along with
those with heart, lung and kidney disease, might be better off
without ribavirin therapy, said the team, led by Dr. Peter
Ferenci of the Medical University of Vienna, Austria.
"Given the known teratogenicity of ribavirin, a
ribavirin-free regiment would also be preferable for some women
of childbearing potential," the researchers say.
Their results come a week and a half after release of the
SAPPHIRE I and II trials, which examined the same regimen --
with ribavirin -- in genotype 1 patients, some of whom had not
received any previous treatment with an interferon regimen.
They found a sustained virologic response in 96% of
volunteers, including those for whom previous treatments had
failed to keep the virus at bay. The typical rate with
interferon therapy is 78% or lower. That study, as with the new
genotype 1 study released Sunday, was financed by AbbVie.
Results from another study released Sunday showed that the
combination of sofosbuvir and ribavirin produced a sustained
virologic response after 12 weeks of therapy in 93% of 73
patients with a hepatitis C virus genotype 2 infection (95%
confidence interval 85 to 98), and in 85% of 250 patients with
HCV genotype 3 disease treated for 24 weeks (95% confidence
interval 80 to 89).
Those two genotypes account for about 30% of chronic HCV
infections.
Fifty eight percent of the patients had previously been
treated with interferon. All were originally supposed to receive
12 weeks of treatment with the drug combination or placebo, but
the rules for patients with genotype 3 infection were changed in
mid-study to provide 24 weeks of therapy and to eliminate the
placebo group.
"Patients receiving sofosbuvir-ribavirin had substantial
reductions in circulating HCV RNA levels during the first weeks
of treatment," said the team, led by Dr. Stefan Zeuzem of the
Johann Wolfgang Goethe University Medical Center in Frankfurt,
Germany. "By week 4 of treatment, 99% of the patients had an HCV
RNA level of less than 25 IU/mL. No patients in the placebo
group had an HCV RNA level of less than 25 IU/mL at any time
point."
That study is called VALENCE. Gilead Sciences paid for the
research.
SOURCES: http://bit.ly/1idkzmx and http://bit.ly/Q6ducg
N Engl J Med 2014
|